Navigation Links
First of many Neuro-Biotech's licensed products, "SymPath(R) blood test"
Date:10/4/2010

BASEL, Switzerland, Oct. 4 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to the company's press release issued the 30th of September 2010, the following is a brief review and explanation of the earlier statements concerning the first of many Neuro-Biotech's licensed products, "SymPath(R) blood test".

For a better understanding, an "in vitro" blood test is described as, a non evasive test, whereas the testing, as in the case of SymPath(R), is performed on a small amount of the patient's blood. To date the SymPath(R) blood test has been tested on several thousand of patients whose results illustrate a success rate accuracy of 98.8%. The testing audits have been rigorously documented and have met every industry standard.

SymPath(R) is an indispensable tool with unprecedented results. Medical practitioners have long been waiting for a similar test to accurately and quantifiably diagnose those symptoms amongst patients as, depression and stress related disorders. What does this mean for physicians?

Firstly, SymPath(R) assists the medical practitioner in diagnosing patients, based on quantitative measurement, as precise as current cholesterol tests. SymPath(R) allows the medical practitioner to determine with accuracy the severity level of the patient's anxiety or depressive state. The medical practitioner will now be able to state, based on an objective quantified measure, using this test, rather than subjectively determining the diagnosis, as is currently performed.

Furthermore SymPath(R) will eliminate the costly and highly inefficient trial and errors currently performed by physicians in prescribing their recommended remedy, which can waste time and further cause harm for both patients and physicians. For instance, patients suffering from depression or stress related disorders will now properly diagnosed immediately following the testing through Neuro-Biotech's SymPath(R) test.

No more g
'/>"/>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... HANOVER, N.J., Dec. 6, 2010 The Novartis ... demonstrated substantial disease control and tumor reduction in ... or had become refractory after an autologous stem ... Phase II clinical trial presented today(1). ...
... 6, 2010 Wells Fargo Practice Finance, formerly known ... preferred provider for optometric practice and equipment financing for ... affinity relationship through the AOA,s Member Advantage Program will ... for practice acquisition, start-up and expansion projects, along with ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 2Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 3
(Date:8/31/2014)... Richmond, CA (PRWEB) August 31, 2014 ... program of the California State Library, celebrates 30 ... and their families. Since its inception, California’s Library ... a million Californians learn to read and write. ... this volunteer-based program, the state is launching a ...
(Date:8/31/2014)... 2014 The severity of menopausal symptoms ... in menopause is expert in helping patients find ... from uncomfortable symptoms with the latest treatment options, including ... a variety of alternative treatments and products that can ... options may fall outside of what can be called ...
(Date:8/31/2014)... Spain Sunday 31 August 2014: Drinking tea reduces ... 000 people presented at ESC Congress today by Professor ... you have to choose between tea or coffee it,s ... important components of our way of life. Their effects ... past with sometimes divergent results. We investigated the effects ...
(Date:8/30/2014)... 2014: Local anaesthetic is as safe and effective for ... to results of the FRANCE 2 registry presented at ... , Dr Chopard said: "Numerous studies have shown that ... severe symptomatic aortic stenosis who are at very high ... The number of TAVI procedures in France and around ...
(Date:8/30/2014)... Orlando, Florida (PRWEB) August 31, 2014 ... gait walking and how a mobility device can help in ... now available for free download from the website that contains ... medical doctor for this site. , The articles deal with ... mobility device like a walking cane can help in making ...
Breaking Medicine News(10 mins):Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2
... of Medicine (IOM) recently released a study, The Future ... calls for new and expanded roles for nurses in ... education for all nurses and allowing nurses to practice ... It advocates overhauling state scope of practice acts and ...
... was diagnosed in 2007 with acute multiple myeloma, a form ... troubles all those who receive an upsetting diagnosis. The way ... however, was different. Barrager drew upon his engineering and management ... is sharing his insights with hospitals and doctors in his ...
... Steven Reinberg HealthDay Reporter , MONDAY, Nov. ... pandemic H1N1 flu last year in California, more than ... California Department of Public Health researchers report. , ... to occur at similar rates as with seasonal influenza, ...
... News) -- Military veterans with psychiatric illnesses are at ... The greatest risk is among males with bipolar disorder ... researchers at the U.S. Department of Veterans Affairs and ... Overall, bipolar disorder (the least common diagnosis at 9 ...
... , MONDAY, Nov. 1 (HealthDay News) -- Any ... removed from play until evaluated by a physician who ... a new position statement issued by the American Academy ... recommendations directed at policymakers who develop procedures to be ...
... MONDAY, Nov. 1 (HealthDay News) -- Stroke patients are more ... the weekend instead of a weekday, regardless of the severity ... analyzed data from almost 21,000 stroke patients admitted to 11 ... their first stroke were included in the study. Seven ...
Cached Medicine News:Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 2Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 3Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 4Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 5Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 6Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 2Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 3Health News: Pandemic H1N1 Flu Hit Kids Hard in 2009 2Health News: Pandemic H1N1 Flu Hit Kids Hard in 2009 3Health News:Bipolar Disorder Tied to High Suicide Risk in Veterans 2Health News:Concussion Should Sideline Athletes: Neurologists 2Health News:Weekend Admissions Worse for Stroke Victims: Study 2
... Compact and durable, the Medelec ... Whether your choice of a smaller ... your need to take your testing ... Notebook is the solution. The 2, ...
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... Myoquick 1200/1400/1800 units are based ... adopt the ISA 100x EP ... can select input units with ... 1002 EP), 4 channels (ISA ...
Sierra II power & efficiency plus. Sierra II report generator with automatic sentence generation creates the one-minute report. Complete 2/4 channel EMG/NCV/EP....
Medicine Products: